Multicentre Study of the Molecular Epidemiology, Serotypes and Antimicrobial Susceptibility Patterns of Invasive Streptococcus pneumoniae Invasive Isolated from Children in the Ille de France Area

  • J.-W. DecousserEmail author
  • P. Ovetchkine
  • A. Collignon
  • C. Chaplain
  • E. Estrangin
  • A. Fremaux
  • P. Reinert
  • P. Foucaud
  • J.-C. Ghnassia
  • R. Cohen
  • J. Gaudelus
  • P.-Y. Allouch


Between January 1997 and April 2002, 73 consecutive invasive strains of Streptococcus pneumoniae were isolated from children under 16 years of age in four hospitals in suburban Paris. Their genetic diversity was investigated by serotyping and analysis of pulsed-field gel electrophoresis restriction patterns. Antibiotic susceptibility patterns were analysed by disk susceptibility testing and determination of minimal inhibitory concentrations. The genetic basis of macrolide resistance was investigated by polymerase chain reaction. Studies of penicillin and vancomycin tolerance were performed for each strain. Despite the high prevalence (45.2%) of penicillin-nonsusceptible Streptococcus pneumoniae, resistance to amoxicillin (1.4%) was rare, and no strain was resistant to cefotaxime. Overall, 4.1% of pneumococcal strains were resistant to penicillin. Penicillin or vancomycin tolerance was not detected in any of the 73 strains studied. Of the erythromycin-resistant strains (48%), all but one carried the ermB gene. No strains showing a decreased susceptibility to ciprofloxacin (MIC, >4 mg/l) or overexpressing an efflux pump inhibited by reserpine were isolated. The serotypes found, in order of frequency, were as follows: 18C, 14, 6B, 19F, 19A, 9V, 23F, 1, 7F, 9A, 38. Strains of penicillin-nonsusceptible Streptococcus pneumoniae belonged predominantly to serotypes 14, 6B, 9V, 9A, 23F, 19F and 19A. The seven-valent conjugated vaccine covered 85.5% of the serogroups isolated in children under 2 years of age and 65.6% of the serogroups identified in children over 2 years of age. The genetic analysis showed a high identity for some serotypes, such as 14/9V, 6B and 23F. The use of the seven-valent conjugated vaccine is a critical measure to prevent invasive pneumococci infections in children in the Ille de France area.


Moxifloxacin Streptococcus Pneumoniae Gatifloxacin Pneumococcal Disease Macrolide Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Floret D, Groupe de Pathologie Infectieuse Pediatrique, Groupe Francophone de Reanimation et d’Urgence Pediatrique (2001) Pediatric deaths due to community-acquired bacterial infection. Survey of French pediatric intensive care units. Arch Pediatr 8 [Suppl 4]:705–711Google Scholar
  2. 2.
    Département des Maladies Infectieuses, InVS (2002) Surveillance nationale des maladies infectieuses 1998–2000.
  3. 3.
    Adam D (2002) Global antibiotic resistance in Streptococcus pneumoniae. J Antimicrob Chemother 50 [Topic T-1]:1–5Google Scholar
  4. 4.
    Doit C, Loukil C, Geslin P, Bingen E (2002) Phenotypic and genetic diversity of invasive pneumococcal isolates recovered from French children. J Clin Microbiol 40:2994–2998CrossRefPubMedGoogle Scholar
  5. 5.
    Moissenet D, Valcin M, Marchand V, Garabedian EN, Geslin P, Garbarg-Chenon A, Vu-Thien H (1997) Molecular epidemiology of Streptococcus pneumoniae with decreased susceptibility to penicillin in a Paris children’s hospital. J Clin Microbiol 351:298–301Google Scholar
  6. 6.
    Doit C, Picard B, Loukil C, Geslin P, Bingen E (2000) Molecular epidemiology survey of penicillin-susceptible and -resistant Streptococcus pneumoniae recovered from patients with meningitis in France. J Infect Dis 181:1971–1978CrossRefPubMedGoogle Scholar
  7. 7.
    Konradsen HB, Kaltoft MS (2002) Invasive pneumococcal infections in Denmark from 1995 to 1999: epidemiology, serotypes, and resistance. Clin Diagn Lab Immunol 9:358–365CrossRefPubMedGoogle Scholar
  8. 8.
    Giebink GS (2001) The prevention of pneumococcal disease in children. N Engl J Med 345:1177–1183PubMedGoogle Scholar
  9. 9.
    Mulholland K (1999) Strategies for the control of pneumococcal diseases. Vaccine 30 [Suppl 1]:79–84Google Scholar
  10. 10.
    Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F (2001) Postlicensure evaluation of the effectiveness of seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 20:1105–1107PubMedGoogle Scholar
  11. 11.
    Sorensen UBS (1993) Typing of pneumococci by using 12 pooled antisera. J Clin Microbiol 31:2097–2100PubMedGoogle Scholar
  12. 12.
    McEllistrem MC, Stout JE, Harrison LH (2000) Simplified protocol for pulsed-field gel electrophoresis analysis of Streptococcus pneumoniae. J Clin Microbiol 38:351–353PubMedGoogle Scholar
  13. 13.
    Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 9:2233–2239Google Scholar
  14. 14.
    Decousser JW, Allouch PY, Courvalin P, Leclercq R (2002) In vitro activity of moxifloxacin against recent community-acquired respiratory tract pathogens isolated in France: a national survey. Int J Antimicrob Agents 20:186–195CrossRefPubMedGoogle Scholar
  15. 15.
    Comité de l’Antibiogramme de la Société Française de Microbiologie (2003) Communiqué 2002. Société Française de Microbiologie.
  16. 16.
    Henriques Normark B, Novak R, Ortqvist A, Kallenius G, Tuomanen E, Normark S (2001) Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin. Clin Infect Dis 15:552–558CrossRefGoogle Scholar
  17. 17.
    Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L (1996) Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 40:2562–2566PubMedGoogle Scholar
  18. 18.
    Bast D, Low D, Duncan C, Kilburn L, Mandell LA, Davidson RJ, De Azavedo JCS (2000) Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother 44:3049–3054CrossRefPubMedGoogle Scholar
  19. 19.
    Markham PN (1999) Inhibition of the emergence of the ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine. Antimicrob Agents Chemother 43:988–989PubMedGoogle Scholar
  20. 20.
    Chouakri O, Ktari F, Lavaud J, Maury I, Lode N, Durand S, Chabernaud JL, Arbaoui H, Lemouchi A, Barbier ML (2001) Severe bacterial infections in children. Survey by the pediatric mobile intensive care unit AP/HP in the Ile-de-France area. Arch Pediatr 8 [Suppl 4]:712–720Google Scholar
  21. 21.
    Gendrel D, Raymond J, Moulin F, Iniguez JL, Ravilly S, Habib F, Lebon P, Kalifa G (1997) Etiology and response to antibiotic therapy of community-acquired pneumonia in French children. Eur J Clin Microbiol Infect Dis 16:388–391PubMedGoogle Scholar
  22. 22.
    Spratt BG, Greenwood BM (2000) Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet 356:1210–1211CrossRefPubMedGoogle Scholar
  23. 23.
    Obaro SK (2002) The new pneumococcal vaccine. Clin Microbiol Infect 8:623–633CrossRefPubMedGoogle Scholar
  24. 24.
    Olivier C, Doit C, Moniot-Ville N, Bensalah A, Laurent C, Bingen B, the French Study Group (2001) Community-acquired bacteremia in children: a one-year survey in France. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract no. G-1525Google Scholar
  25. 25.
    Doit C, Loukil C, Fitoussi F, Geslin P, Bingen E (1999) Emergence in France of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxycillin. Antimicrob Agents Chemother 43:1480–1483PubMedGoogle Scholar
  26. 26.
    Harbarth S, Albrich W, Brun-Buisson C (2002) Outpatient antibiotic use and prevalence of antibiotic-resistant pneumococci in France and Germany: a sociocultural perspective. Emerg Infect Dis 8:1460–1467PubMedGoogle Scholar
  27. 27.
    Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C, Bouza E, Aguilar L, Garcia-de-Lomas J, Baquero F, and the Spanish Surveillance Group for Respiratory Pathogens (2001) Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998–1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 45:3334–3340CrossRefPubMedGoogle Scholar
  28. 28.
    Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa de Echaguen A, Gareen IF, Reiss PT, Medeiros AA (2002) Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 35:556–564CrossRefPubMedGoogle Scholar
  29. 29.
    Fitoussi F, Doit C, Geslin P, Brahimi N, Bingen E (2001) Mechanisms of macrolide resistance in clinical pneumococcal isolates in France. Antimicrob Agents Chemother 45:63663–63668Google Scholar
  30. 30.
    Angot P, Vergnaud M, Auzou M, Leclercq R (2000) Macrolide resistance phenotypes and genotypes in French clinical isolates of Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 19:755–758CrossRefPubMedGoogle Scholar
  31. 31.
    Hyde TB, Gay K, Stephens DS, Vugia DJ, Pass M, Johnson S, Barrett NL, Schaffner W, Cieslak PR, Maupin PS, Zell ER, Jorgensen JH, Facklam RR, Whitney CG, the Active Bacterial Core Surveillance/Emerging Infections Program Network (2001) Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 286:1857–1862CrossRefPubMedGoogle Scholar
  32. 32.
    Gendrel D, Moulin F (2001) Fluoroquinolones in paediatrics. Paediatr Drugs 3:365–377PubMedGoogle Scholar
  33. 33.
    Mandell LA, Peterson LR, Wise R, Hooper D, Low DE, Schaad UB, Klugman KP, Courvalin P (2002) The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin Infect Dis 35:721–727CrossRefPubMedGoogle Scholar
  34. 34.
    Henriques Normark B, Normark S (2002) Antibiotic tolerance in pneumococci. Clin Microbiol Infect 8:613–622CrossRefPubMedGoogle Scholar
  35. 35.
    Mitchell L, Tuomanen E (2001) Vancomycin-tolerant Streptococcus pneumoniae and its clinical significance. Pediatr Infect Dis J 20:531–533CrossRefPubMedGoogle Scholar
  36. 36.
    Azoulay-Dupuis E, Moine P, Bedos JP, Rieux V, Vallee E (1996) Amoxycillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains. Antimicrob Agents Chemother 40:941–946PubMedGoogle Scholar
  37. 37.
    McCullers JA, English BK, Novak R (2000) Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis J Infect Dis 181:369–373Google Scholar
  38. 38.
    Tuomanen E, Durack DT, Tomasz A (1986) Antibiotic tolerance among clinical isolates of bacteria. Antimicrob Agents Chemother 30:521–527PubMedGoogle Scholar
  39. 39.
    Novak R, Henriques B, Charpentier E, Normark S, Tuomanen E (1999) Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 399:590–593PubMedGoogle Scholar
  40. 40.
    Bourrillon A, Doit C, Bingen E (1998) Childhood bacterial meningitis. Antibiotic strategies. Presse Med 27:1183–1186PubMedGoogle Scholar
  41. 41.
    Anton N, Blazquez R, Gomez-Garces JL, Alos JI (2001) Study of vancomycin tolerance in 120 strains of Streptococcus pneumoniae isolated in 1999 in Madrid, Spain. J Antimicrob Chemother 47:902–903CrossRefPubMedGoogle Scholar
  42. 42.
    Geslin P, Fremaux A, Sissia G, Spicq C (1998) Streptococcus pneumoniae: sérotypes, souches invasives et résistantes aux antibiotiques. Situation actuelle en France. Presse Méd 27 [Suppl 1]:21–26Google Scholar
  43. 43.
    Dagan R, Gradstein S, Belmaker I, Porat N, Siton Y, Weber G, Janco J, Yagupsky P (2000) An outbreak of Streptococcus pneumoniae serotype 1 in a closed community in southern Israel. Clin Infect Dis 30:319–321CrossRefPubMedGoogle Scholar
  44. 44.
    Byington CL, Spencer LY, Johnson TA, Pavia AT, Allen D, Mason EO, Kaplan S, Carroll KC, Daly JA, Christenson JC, Samore MH (2002) An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin Infect Dis 34:434–440CrossRefPubMedGoogle Scholar
  45. 45.
    Eltringham G, Kearns A, Freeman R, Clark J, Spencer D, Eastham K, Harwood J, Leeming J (2003) Culture-negative childhood empyema is usually due to penicillin-sensitive Streptococcus pneumoniae capsular serotype 1. J Clin Microbiol 41:521–522CrossRefPubMedGoogle Scholar
  46. 46.
    Henriques Normark B, Kalin M, Ortqvist A, Akerlund T, Liljequist BO, Hedlund J, Svenson SB, Zhou J, Spratt BG, Normark S, Kallenius G (2001) Dynamics of penicillin-susceptible clones in invasive pneumococcal disease. J Infect Dis 184:861–869CrossRefPubMedGoogle Scholar
  47. 47.
    Richter SS, Heilmann KP, Coffman SL, Huynh HK, Brueggemann AB, Pfaller MA, Doern GV (2002) The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994–2000. Clin Infect Dis 34:330–339CrossRefPubMedGoogle Scholar
  48. 48.
    Vilhelmsson SE, Tomasz A, Kristinsson KG (2000) Molecular evolution in a multidrug-resistant lineage of Streptococcus pneumoniae: emergence of strains belonging to the serotype 6B Icelandic clone that lost antibiotic resistance traits. J Clin Microbiol 38:1375–1381PubMedGoogle Scholar
  49. 49.
    Setchanova L, Tomasz A (1999) Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates from Bulgaria. J Clin Microbiol 37:638–648PubMedGoogle Scholar
  50. 50.
    Ferroni A, Nguyen L, Gehanno P, Boucot I, Berche P (1996) Clonal distribution of penicillin-resistant Streptococcus pneumoniae 23F in France. J Clin Microbiol 34:2707–2712PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • J.-W. Decousser
    • 1
    Email author
  • P. Ovetchkine
    • 2
  • A. Collignon
    • 3
  • C. Chaplain
    • 4
  • E. Estrangin
    • 5
  • A. Fremaux
    • 5
  • P. Reinert
    • 6
  • P. Foucaud
    • 7
  • J.-C. Ghnassia
    • 8
  • R. Cohen
    • 5
  • J. Gaudelus
    • 2
  • P.-Y. Allouch
    • 1
  1. 1.Department of Hospital HealthCentre Hospitalier de VersaillesLe Chesnay CedexFrance
  2. 2.Paediatric DepartmentCentre Hospitalier Universitaire Jean VerdierBondyFrance
  3. 3.Department of MicrobiologyCentre Hospitalier Universitaire Jean VerdierBondyFrance
  4. 4.Department of MicrobiologyCentre Hospitalier de Saint-DenisSaint-DenisFrance
  5. 5.Department of MicrobiologyCentre Hospitalier Intercommunal de CréteilCréteilFrance
  6. 6.Paediatric DepartmentCentre Hospitalier Intercommunal de CréteilCréteilFrance
  7. 7.Paediatric DepartmentCentre Hospitalier de VersaillesLe Chesnay CedexFrance
  8. 8.Department of MicrobiologyCentre Hospitalier de VersaillesLe Chesnay CedexFrance

Personalised recommendations